Nowa wersja platformy jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2012 | 7 | 5 | 591-595
Tytuł artykułu

Plasma serotonin level in left-sided colonic diverticulosis: A pilot study

Treść / Zawartość
Warianty tytułu
Języki publikacji
Neurotransmitters might participate in the development of diverticular disease. We measured fasting and postprandial serotonin levels in colonic diverticulosis patients and healthy volunteers. We demonstrated significantly lower maximal concentrations of serotonin in patients than the controls (respectively 109.8±61.4 and 251.3±44.1 ng/ml, p<0.001) as well as lower serotonin minimal values (respectively 38.4±21.8 and 124.6±41.4 ng/ml, p<0.001) and areas under time-course curves (respectively 288.8±139.8 and 739±167.4 ng/ml, p<0.001); significant difference between alternating pattern and normal bowel habit concerning fasting serotonin level, the hormone response to test meal (p=0.041) as well as minimal serotonin level (p=0.044). Bowel habit was also related to peak serotonin values following a test meal with 38.5 ng/ml in constipation, 139.5 ng/ml in diarrhea, 122.4 ng/ml in alternating pattern and 249 ng/ml in subjects with normal bowel habit (p=0.040) as well as AUC with 120.8 ng/ml in constipation, 416 ng/ml in diarrhea, 298 ng/ml in alternating pattern and 684 ng/ml in subjects with normal bowel habit (p=0.043). We demonstrated substantial differences in fasting serum serotonin levels as well as the hormone response to a test meal between colonic diverticulosis patients and healthy individuals, which seemed to be associated with abnormal bowel habits rather than presence of diverticula.
Słowa kluczowe

Opis fizyczny
  • Department of Gastroenterology and Hepatology, Wroclaw Medical University, Borowska 213, 50-556, Wroclaw, Poland,
  • Department of Medical Biochemistry, Wroclaw Medical University, Chalubinskiego 10, 50-368, Wroclaw, Poland
  • Department of Gastroenterology and Hepatology, Wroclaw Medical University, Borowska 213, 50-556, Wroclaw, Poland
  • [1] Neubauer K., Dudkowiak R., Paradowski L., Leftsided diverticulosis of the large bowel as the second most common abnormality in colonoscopy - review of 425 cases of colonic diverticulosis, Adv. Clin. Exp. Med., 2010, 19, 513–518
  • [2] Nguyen G.C., Sam J., Anand N., Epidemiological trends and geographic variation in hospital admissions for diverticulitis in the United States, World J. Gastroenterol., 2011, 17, 1600–1605[WoS][Crossref]
  • [3] Jeyarajah S., Faiz O., Bottle A., Aylin P., Bjarnason I., Tekkis P.P., et al., Diverticular disease hospital admissions are increasing, with poor outcomes in the elderly and emergency admissions, Aliment. Pharmacol. Ther., 2009, 30, 1171–1182[Crossref][WoS]
  • [4] Jeyarajah S., Papagrigoriadis S., Review article: the pathogenesis of diverticular disease - current perspectives on motility and neurotransmitters, Aliment. Pharmacol. Ther., 2011, 33, 789–800[Crossref][WoS]
  • [5] Sikander A., Rana S.V., Prasad K.K., Role of serotonin in gastrointestinal motility and irritable bowel syndrome, Clin. Chim. Acta., 2009, 403, 47–55[Crossref][WoS]
  • [6] Banerjee S., Akbar N., Moorhead J., Rennie J.A., Leather A.J., Cooper D., Increased presence of serotonin-producing cells in colons with diverticular disease may indicate involvement in the pathophysiology of the condition, Int. J. Colorectal. Dis., 2007, 6, 643–649[Crossref][WoS]
  • [7] Costedio M.M., Coates M.D., Danielson A.B., Buttolph T.R. 3rd, Blaszyk H.J., Mawe G.M., et al., Serotonin signaling in diverticular disease, J. Gastrointest. Surg., 2008, 12, 1439–1445[Crossref][WoS]
  • [8] Spiller R., Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease, Neurogastroenterol. Motil., 2007, 19(Suppl. 2), 25–31[WoS][Crossref]
  • [9] Tan K.Y, Seow-Chowen F., Fiber and colorectal diseases: separating fact from fiction, World J. Gastroenterol., 2007, 13, 4161–4167
  • [10] Spiller R.C.L., Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome, Curr. Opin. Pharmacol., 2011, 11, 68–74[Crossref]
  • [11] Ford A.C., Brandt L.J., Young C., Chey W.D., Foxx-Orenstein A.E., Moayyedi P., Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis, Am. J. Gastroenterol., 2009, 104, 1831–1843[Crossref]
  • [12] Tursi A., Diverticular disease: a therapeutic overview, World J. Gastrointest. Pharmacol. Ther., 2010, 1, 27–35[Crossref]
  • [13] Dunlop S.P., Coleman N.S., Blackshow E., Perkins A.C., Singh G., Mardsen C.A., Spiller R.C., Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 2005, 3, 349–357[Crossref]
  • [14] Atkinson W., Lockhart S., Whorwell P.J., Keevil B., Houghton L.A., Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome, Gastroenterology, 2006, 130, 34–43[Crossref]
  • [15] Bearcroft C.P., Perrett D., Farthing M.J.G., Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study, Gut, 1998, 42, 42–46[Crossref]
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.